Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial.

@article{Goldstein2001SelectiveS1,
  title={Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial.},
  author={David John Goldstein and Krista I Roon and Walter W. Offen and Nabih M. Ramadan and Lee Phebus and Keith W. Johnson and John M. Schaus and Michel D. Ferrari},
  journal={Lancet},
  year={2001},
  volume={358 9289},
  pages={1230-4}
}
BACKGROUND Triptans (5-HT(1B/1D) receptor agonists) are effective drugs for acute migraine, but the side-effect of coronary vasoconstriction restricts their use in patients who are at risk of coronary artery disease. We have studied the efficacy of LY334370, a selective serotonin 1F (5-HT(1F)) receptor agonist with preclinical efficacy and no vasoconstriction, for migraine relief. METHODS We gave LY334370 (20, 60, or 200 mg) or placebo to 99 outpatients with moderate or severe migraine… CONTINUE READING